RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The flowers have five free stamens with short free filaments that are oppressed against the ovary, with a dorsal connective appendage that is large, entire and oblong to ovate. Only the lower two stamens are calcarate (possessing nectary spurs that are inserted on the lowest petal into the spur or a pouch). The styles are filiform (threadlike) or clavate (clubshaped), thickened at their tip, being globose to rostellate (beaked). The stigmas are head-like, narrowed or often beaked. The flowers have a superior ovary with one cell, which has three placentae, containing many ovules. After flowering, fruit capsules are produced that are thick walled, with few to many seeds per carpel, and dehisce (split open) by way of three valves. On drying, the capsules may eject seeds with considerable force to distances of several meters. The nutlike seeds, which are obovoid to globose, are typically arillate (with a specialized outgrowth) and have straight embryos, flat cotyledons, and soft fleshy endosperm that is oily.
A functional beverage is a drink marketed to highlight specific product ingredients or supposed health effects. Beverages marketed as "functional" include dairy drinks, sports and performance drinks, energy drinks, ready-to-drink teas, kombucha, "smart" drinks, fortified fruit drinks, plant milks, and enhanced water. Although these beverages may serve to hydrate a consumer, they have no proven health effects, and accordingly appear not to be "functional". For example, there is no good clinical evidence that kombucha provides any benefit to human health.
A mortar attack by insurgents killed six civilians and wounded 14 whereas two policemen were injured by sniper fire during the operation in Hangu, following which Pakistani forces took control of the area. Two children were killed and four were injured in crossfire during a skirmish in Bajaur District. On 7-8 May 2026, Pakistani forces conducted two operations in Dera Ismail Khan and Tank District, killing five militants. On 8 May 2026, eight civilians were injured in a quadcopter strike in Bannu District. A police constable was killed by militants after his abduction in Bajaur. On 9 May 2026, a car bomb exploded at a Pakistani checkpoint in Bannu, leaving at least 21 dead. Ittehad-ul-Mujahideen Pakistan, a Pakistani Taliban splinter group, claimed responsibility for the attack. On 10 May 2026, an Al-Qaeda affiliate was arrested by CTD in Pakpattan District. Pakistani forces killed seven militants including two key commanders, and destroyed militant infrastructure in a clearance operation in North Waziristan District. On 11 May 2026, a civilian was killed while foiling a suicide bombing in Attock District. On 12 May 2025, UNAMA stated that 372 civilians were killed and 397 had been wounded in Pakistani strikes on Afghanistan. On 13 May 2026, nine people including two traffic police personnel were killed and 33 injured in a VBIED attack by TTP in Lakki Marwat District, TTP militants also blew up a bridge in Bannu District. TTP militants captured a bank van and robbed PKR 80M. CM Khyber Pakhtunkhwa claimed that 80% of militants operating in the province were foreigners.
Sources: en.wikipedia.org
The government also introduced facilitation measures for international media, including visa-on-arrival arrangements for foreign journalists covering the talks and shuttle transport services between designated media area, Jinnah Convention Centre, and Serena Hotel.
== Classification == Wounds can be broadly classified as either acute or chronic based on time from initial injury and progression through normal stages of wound healing. Both wound types can further be categorized by cause of injury, wound severity/depth, and sterility of the wound bed. Several classification systems have been developed to describe wounds and guide their management. Some notable classification systems include the CDC's Surgical Wound Classification, the International Red Cross Wound Classification, the Tscherne classification, the Gustilo-Anderson classification of open fractures, and the AO soft tissue grading system.
Lulu Mall Hyderabad is a shopping mall located in Hyderabad, the capital city of Telangana, India. It is the first lulu mall in the state of Telangana, located in Kukatpally. The mall was inaugurated in September 2023 and houses shops for both domestic and international brands as well as a multi-cuisine food court, a theatre, and other amenities. The estimated cost for this project was more than ₹300 crore. The property is owned and managed by Abu Dhabi based LuLu Group International.
Sources: en.wikipedia.org
== Mechanism of action == T3 and T4 bind to nuclear receptors (thyroid hormone receptors). T3 and T4, although being lipophilic, are not able to passively diffuse through the phospholipid bilayers of target cells, instead relying on transmembrane iodothyronine transporters. The lipophilicity of T3 and T4 requires their binding to the protein carrier thyroid-binding protein (TBG) (thyroxine-binding globulins, thyroxine binding prealbumins, and albumins) for transport in the blood. The thyroid receptors bind to response elements in gene promoters, thus enabling them to activate or inhibit transcription. The sensitivity of a tissue to T3 is modulated through the thyroid receptors.
The concept of a steady state has relevance in many fields, in particular thermodynamics, economics, and engineering. If a system is in a steady state, then the recently observed behavior of the system will continue into the future. In stochastic systems, the probabilities that various states will be repeated will remain constant. For example, see Linear difference equation § Conversion to homogeneous form for the derivation of the steady state. In many systems, a steady state is not achieved until some time after the system is started or initiated. This initial situation is often identified as a transient state, start-up or warm-up period. For example, while the flow of fluid through a tube or electricity through a network could be in a steady state because there is a constant flow of fluid or electricity, a tank or capacitor being drained or filled with fluid is a system in transient state, because its volume of fluid changes with time. Often, a steady state is approached asymptotically. An unstable system is one that diverges from the steady state. See for example Linear difference equation#Stability. In chemistry, a steady state is a more general situation than dynamic equilibrium. While a dynamic equilibrium occurs when two or more reversible processes occur at the same rate, and such a system can be said to be in a steady state, a system that is in a steady state may not necessarily be in a state of dynamic equilibrium, because some of the processes involved are not reversible. In other words, dynamic equilibrium is just one manifestation of a steady state.
=== Digital ion trap === The digital ion trap (DIT) is a quadrupole ion trap (linear or 3D) that differs from conventional traps by the driving waveform. A DIT is driven by digital signals, typically rectangular waveforms that are generated by switching rapidly between discrete voltage levels. Major advantages of the DIT are its versatility and virtually unlimited mass range. The digital ion trap has been developed mainly as a mass analyzer.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.